Screening for hepatocellular carcinoma and cholangiocarcinoma

Can biomarkers replace imaging?

Maria E. Lozada, Roongruedee Chaiteerakij, Lewis Rowland Roberts

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Treatment of liver and biliary tract cancer is most effective for early and localized disease. Effective screening methods for hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) will lead to early detection and treatment, and thus improvement in survival. Patients at risk of developing HCC and CCA will benefit the most from effective surveillance strategies. In this review, we provide an update on the current status of HCC and CCA surveillance and describe the recent efforts on biomarker development.

Original languageEnglish (US)
Article numberA004
Pages (from-to)128-138
Number of pages11
JournalCurrent Hepatitis Reports
Volume14
Issue number2
DOIs
StatePublished - Jun 1 2015

Fingerprint

Cholangiocarcinoma
Hepatocellular Carcinoma
Biomarkers
Biliary Tract Neoplasms
Survival
Liver
Therapeutics

Keywords

  • Bile duct cancer
  • Diagnosis
  • Early detection
  • Liver cancer
  • Surveillance

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Screening for hepatocellular carcinoma and cholangiocarcinoma : Can biomarkers replace imaging? / Lozada, Maria E.; Chaiteerakij, Roongruedee; Roberts, Lewis Rowland.

In: Current Hepatitis Reports, Vol. 14, No. 2, A004, 01.06.2015, p. 128-138.

Research output: Contribution to journalArticle

@article{3e54b3f11fb0499ca640f937d60a91b9,
title = "Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging?",
abstract = "Treatment of liver and biliary tract cancer is most effective for early and localized disease. Effective screening methods for hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) will lead to early detection and treatment, and thus improvement in survival. Patients at risk of developing HCC and CCA will benefit the most from effective surveillance strategies. In this review, we provide an update on the current status of HCC and CCA surveillance and describe the recent efforts on biomarker development.",
keywords = "Bile duct cancer, Diagnosis, Early detection, Liver cancer, Surveillance",
author = "Lozada, {Maria E.} and Roongruedee Chaiteerakij and Roberts, {Lewis Rowland}",
year = "2015",
month = "6",
day = "1",
doi = "10.1007/s11901-015-0261-y",
language = "English (US)",
volume = "14",
pages = "128--138",
journal = "Current Hepatitis Reports",
issn = "1540-3416",
publisher = "Springer Publishing Company",
number = "2",

}

TY - JOUR

T1 - Screening for hepatocellular carcinoma and cholangiocarcinoma

T2 - Can biomarkers replace imaging?

AU - Lozada, Maria E.

AU - Chaiteerakij, Roongruedee

AU - Roberts, Lewis Rowland

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Treatment of liver and biliary tract cancer is most effective for early and localized disease. Effective screening methods for hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) will lead to early detection and treatment, and thus improvement in survival. Patients at risk of developing HCC and CCA will benefit the most from effective surveillance strategies. In this review, we provide an update on the current status of HCC and CCA surveillance and describe the recent efforts on biomarker development.

AB - Treatment of liver and biliary tract cancer is most effective for early and localized disease. Effective screening methods for hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) will lead to early detection and treatment, and thus improvement in survival. Patients at risk of developing HCC and CCA will benefit the most from effective surveillance strategies. In this review, we provide an update on the current status of HCC and CCA surveillance and describe the recent efforts on biomarker development.

KW - Bile duct cancer

KW - Diagnosis

KW - Early detection

KW - Liver cancer

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=84943234689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943234689&partnerID=8YFLogxK

U2 - 10.1007/s11901-015-0261-y

DO - 10.1007/s11901-015-0261-y

M3 - Article

VL - 14

SP - 128

EP - 138

JO - Current Hepatitis Reports

JF - Current Hepatitis Reports

SN - 1540-3416

IS - 2

M1 - A004

ER -